Clinical trial · Interventional
Home Transfusion for HEME
A Home Transfusion Program for Patients With Advanced Hematologic Malignancies
NCT05509439CI-TRIAL-00095803completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancy | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Home Transfusion Program Components | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Home Transfusion
- description
- This research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed. * Home Transfusion Program Components * Participants will be in the research study for up to six months
- interventionNames
- Other: Home Transfusion Program Components
Primary outcomes (2)
- measure
- Enrollment Rate
- timeFrame
- 6 months
- description
- Number of patients consented to the study divided by eligible patients approached by the study team
- measure
- Completion of Home Transfusions and Patient-Reported Data
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:
* Patients with advanced hematologic malignancies:
* Diagnosis of a hematologic malignancy
* Age ≥ 18 years
* Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
* Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction
* Physician-estimated prognosis of six months or less
* Has an adult informal caregiver that lives in the same residence
* Patient resides within catchment served by Care Dimensions Hospice
* Caregivers:
* Identified informal caregiver of enrolled patient with hematologic malignancy
* Age ≥ 18 years
Exclusion Criteria:
* Patients
* Age \< 18 years
* Does not have an identified adult informal caregiver who lives in the same residence
* History of previous serious adverse transfusion reaction
* Presence of decompensated congestive heart failure
* Caregiver
* Age \< 18 years
* Our study will exclude members of the following special populations:
* Adults unable to consent
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* PrisonersReferences
Publications (0)
Data not yet available
No reference posted for this study.